<DOC>
	<DOCNO>NCT02138084</DOCNO>
	<brief_summary>The purpose study provide dose recommendation coadministration BMS-663068 Rifabutin without Ritonavir upcoming Phase 3 study prescribe information purpose</brief_summary>
	<brief_title>Drug-drug Interaction ( DDI ) Rifabutin</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . 1 . Signed Written Informed Consent ) Signed write informed consent must obtain subject accordance requirement study center 's Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) initiation protocolrequired procedure 2 . Target Population ) Healthy subject determine clinically significant deviation normal medical history , physical examination finding , 12lead ECG measurement , clinical laboratory test result b ) Body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive BMI = weight ( kg ) / [ height ( ) ] 2 c ) Subject Reenrollment : This study permit reenrollment subject discontinue study pretreatment failure ( ie , subject randomized/has dose ) . If reenrolled , subject must reconsented 3 . Age Reproductive Status ) Men woman , age 18 50 year , inclusive b ) Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) within 24 hour prior start study drug c ) Women must breastfeed ) WOCBP must agree follow instruction method ( ) contraception duration treatment plus 5 halflives Rifabutin ( 13 day ) plus 30 day ( duration ovulatory cycle ) total 43 day posttreatment completion e ) Men sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment plus 5 halflives Rifabutin ( 13 day ) plus 90 day ( duration sperm turnover ) total 103 day posttreatment completion Medical History Concurrent Diseases ) Any significant acute chronic medical illness determine Investigator . b ) Current recent ( within 3 month study drug administration ) gastrointestinal disease c ) Any major surgery within 4 week study drug administration ) Any gastrointestinal surgery could impact upon absorption study drug e ) Intractable diarrhea ( â‰¥6 loose stool per day least 7 consecutive day ) within 30 day prior first dose study drug f ) History acute chronic pancreatitis g ) History active latent tuberculosis recent exposure someone tuberculosis h ) History uveitis and/or current eye vision problem exception corrective lens ) Contact lens use study drug administration need contact lens study drug administration j ) Donation blood blood bank clinical study ( except screen visit ) within 4 week study drug administration ( within 2 week plasma donation ) k ) Blood transfusion within 4 week study drug administration . l ) History hemolytic disorder , include druginduced hemolysis . ) Inability tolerate oral medication n ) Inability venipunctured and/or tolerate venous access ) Recent ( within 6 month study drug administration ) history smoke current smoker p ) Recent ( within 6 month study drug administration ) drug alcohol abuse define Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) , Diagnostic Criteria Drug Alcohol Abuse q ) Any sound medical , psychiatric , and/or social reason determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>